Posts
Knight of Malta John F. Queeny: Founder of Monsanto
According to the Count in Venice, John Francis Queeny (founder of The Monsanto Company) was a Knight of Malta. Irish-American ROMAN Catholic Queeny (1859-1933) founded Monsanto in 1901 within the Jesuit stronghold of St. Lewis - hosting the Black Pope’s Saint Louis University since 1818.
This is the same year J. P. Morgan, Papal Knight of the Order of Saints Maurice and Lazarus, founded U.S. Steel Corporation and in 1911 would appoint Knight of Malta John A. Farrell as its president. Interesting: Queeny, Morgan and Farrell were all wicked, pope-serving, White Gentiles - not a Jew in the mix!
Robert B. Shapiro was Monsanto’s CEO from 1995 to 2000. The devil’s Great Conspiracy for world government must always appear to be led by Jews, never by the Pope of Rome using select, Masonic "Court Jews" as his underlings!
Once the manufacturer of the now outlawed DDT and Agent Orange during Francis Cardinal Spellman’s CIA-directed Vietnam War, the company also developed and now markets bovine growth hormone, further poisoning the food chain here in America. It is most intriguing that Europe - the pope’s Revived Holy Roman Empire deceptively called "The European Union" - refuses to purchase beef produced in the United States!
Upon purchasing G. D. Searle and Company in 1985, Monsanto, via its NutraSweet Company, is the manufacturer of Aspartame, the notorious neuro-toxin sold to the public as an artificial sweetener. Aspartame is the "artificial sweetener" in the soft drink "Diet Pepsi," Pepisico once employing JFK assassin / FBI liaison to the Warren Commission and Knight of Malta Cartha D. DeLoach.
Monsanto also has strong ties to The Walt Disney Company, with financial backing from the Order’s Bank of America founded in Jesuit-ruled San Francisco by Italian-American ROMAN Catholic Knight of Malta Amadeo Giannini in 1904. Disney owns ABC Television Network and its Director Emeritus is Roy Disney (brother of the late Walt Disney) who was inducted into the Knights of St. Gregory during the same ceremony with Fox Network owner Rupert Murdoch. ABC and Fox are both controlled by Rome through brother Knights of the Order of St. Gregory!
While prior to World War I America relied heavily on foreign supplies of chemicals, the increasing likelihood of U.S. intervention meant that the country would soon need its own domestic producer of chemicals. Looking back on the significance of the war for Monsanto, Queeny's son Edgar remarked, "There was no choice other than to improvise, to invent and to find new ways of doing all the old things. The old dependence on Europe [Hitler's IG Farben in Nazi Germany] was, almost overnight, a thing of the past." Among other problems, Monsanto researchers discovered that pages describing German chemical processes had been ripped out of library books. Monsanto developed several pharmaceutical products, including phenol as an antiseptic, in addition to acetylsalicyclic acid, or aspirin.
Under Edgar Queeny's direction Monsanto, now the Monsanto Chemical Company, began to substantially expand and enter into an era of prolonged growth. Acquisitions expanded Monsanto's product line to include the new field of petrochemical plastics and the manufacture of phosphorus.
In 1979 a lawsuit was filed against Monsanto and other manufacturers of agent orange, a defoliant used during the Vietnam War. Agent orange contained a highly-toxic chemical known as dioxin, and the suit claimed that hundreds of veterans had suffered permanent damage because of the chemical. In 1984 Monsanto and seven other manufacturers agreed to a $180 million settlement just before the trial began. With the announcement of a settlement Monsanto's share price, depressed because of the uncertainty over the outcome of the trial, rose substantially.
Also in 1984, Monsanto lost a $10 million antitrust suit to Spray-Rite, a former distributor of Monsanto agricultural herbicides. The U.S. Supreme Court upheld the suit and award, finding that Monsanto had acted to fix retail prices with other herbicide manufacturers.
In August 1985, Monsanto purchased G. D. Searle, the "NutraSweet" firm. NutraSweet, an artificial sweetener, had generated $700 million in sales that year, and Searle could offer Monsanto an experienced marketing and a sales staff as well as real profit potential - not to mention the fact that Searle's CEO Secretary of Defense Donald Rumsfeld was well-connected among a cabal of corrupt politicians in Washington DC. Since the late 1970s the company had sold nearly 60 low-margin businesses and, with two important agriculture product patents expiring in 1988, a major new cash source was more than welcome. What Monsanto didn't count on, however, was the controversy surrounding Searle's intrauterine birth control device called the Copper-7.
Soon after the acquisition, disclosures about hundreds of lawsuits over Searle's IUD surfaced and turned Monsanto's takeover into a public relations disaster. The disclosures, which inevitably led to comparisons with those about A. H. Robins, the Dalkan Shield manufacturer that eventually declared Chapter 11 bankruptcy, raised questions as to how carefully Monsanto management had considered the acquisition. In early 1986 Searle discontinued IUD sales in the United States. By 1988 Monsanto's new subsidiary faced an estimated 500 lawsuits against the Copper-7 IUD. As the parent company, Monsanto was well insulated from its subsidiary's liabilities by the legal "corporate veil".
Toward the end of the 1980s, Monsanto faced continued challenges from a variety of sources, including government and public concern over hazardous wastes, fuel and feedstock costs, and import competition. At the end of the 99th Congress, then President Ronald Reagan signed a $8.5 billion, five-year cleanup superfund reauthorization act. Built into the financing was a surcharge on the chemical industry created through the tax reform bill. Biotechnology regulations were just being formulated, and Monsanto, which already had types of genetically engineered bacteria ready for testing, was poised to be an active participant in the GMO biotech field.
In keeping with its strategy to become a leader in the health field, Monsanto and the Washington University Medical School entered into a five-year research contract in 1984. Two-thirds of the research was to be directed into areas with obviously commercial applications, while one-third of the research was to be devoted to theoretical work. One particularly promising discovery involved the application of the bovine growth factor, MARKETED as a way to greatly increase milk production.
In the burgeoning low-calorie sweetener market, challengers to NutraSweet were putting pressure on Monsanto. Pfizer Inc., a pharmaceutical company, was preparing to market its product, called alitame, which it claimed was far sweeter than NutraSweet and better suited for baking.
In an interview with Business Week, senior vice-president for research and development Howard Schneiderman commented, "To maintain our markets - and not become another steel industry - we must spend on research and development." Monsanto, which has committed 8% of its operating budget to research and development, far above the industry average, hoped to emerge in the 1990s as one of the leaders in the fields of biotechnology and pharmaceuticals that are only now emerging from their nascent stage.
By the end of the 1980s, Monsanto had restructured itself and become a producer of specialty chemicals, with a focus on biotechnology products. Monsanto enjoyed consecutive record years in 1988 and 1989 - sales were $8.3 billion and $8.7 billion, respectively. In 1988 the Food and Drug Administration (FDA) approved Cytotec, a drug that prevents gastric ulcers in high-risk cases. Sales of Cytotec in the United States reached $39 million in 1989.
The Monsanto Chemical Co. unit prospered with products like Saflex, a type of nylon carpet fiber. The NutraSweet Company held its own in 1989, contributing $180 million in earnings, with growth in the carbonated beverage segment (which Monsanto originated from since 1901 seed money from Coca-Cola to produce carcinogenic Saccharin). Almost 500 new products containing NutraSweet were introduced in 1989, for a total of 3,000 products.
Monsanto continued to invest heavily in research and development, with 7% of sales allotted for R&D. The investment began to pay off when the research and development department developed an all-natural fat substitute called Simplesse. The FDA declared in early 1990 that the Simplesse product was "generally recognized as safe" (GRAS) for use in frozen desserts. That year, the NutraSweet Company introduced Simple Pleasures frozen dairy dessert. Monsanto hoped to see Simplesse used eventually in salad dressings, yogurt, and mayonnaise.
Despite these successes, Monsanto remained frustrated by delays in obtaining FDA approval for bovine somatotropin (BST), a hormore chemical MARKETED to increase milk production in cows that causes mastitis (pus milk). Opponents to BST said it would upset the balance of supply and demand for milk, but Monsanto countered that BST would provide high-quality food supplies to consumers worldwide.
The final year of the 1980s also marked Monsanto's listing for the first time on the Tokyo Stock Exchange. Monsanto officials expected the listing to improve opportunities for licensing and joint venture agreements.
Link: http://bestmeal.info/monsanto/company-history.shtml#timeline
... to be continued
According to the Count in Venice, John Francis Queeny (founder of The Monsanto Company) was a Knight of Malta. Irish-American ROMAN Catholic Queeny (1859-1933) founded Monsanto in 1901 within the Jesuit stronghold of St. Lewis - hosting the Black Pope’s Saint Louis University since 1818.
This is the same year J. P. Morgan, Papal Knight of the Order of Saints Maurice and Lazarus, founded U.S. Steel Corporation and in 1911 would appoint Knight of Malta John A. Farrell as its president. Interesting: Queeny, Morgan and Farrell were all wicked, pope-serving, White Gentiles - not a Jew in the mix!
Robert B. Shapiro was Monsanto’s CEO from 1995 to 2000. The devil’s Great Conspiracy for world government must always appear to be led by Jews, never by the Pope of Rome using select, Masonic "Court Jews" as his underlings!
Once the manufacturer of the now outlawed DDT and Agent Orange during Francis Cardinal Spellman’s CIA-directed Vietnam War, the company also developed and now markets bovine growth hormone, further poisoning the food chain here in America. It is most intriguing that Europe - the pope’s Revived Holy Roman Empire deceptively called "The European Union" - refuses to purchase beef produced in the United States!
Upon purchasing G. D. Searle and Company in 1985, Monsanto, via its NutraSweet Company, is the manufacturer of Aspartame, the notorious neuro-toxin sold to the public as an artificial sweetener. Aspartame is the "artificial sweetener" in the soft drink "Diet Pepsi," Pepisico once employing JFK assassin / FBI liaison to the Warren Commission and Knight of Malta Cartha D. DeLoach.
Monsanto also has strong ties to The Walt Disney Company, with financial backing from the Order’s Bank of America founded in Jesuit-ruled San Francisco by Italian-American ROMAN Catholic Knight of Malta Amadeo Giannini in 1904. Disney owns ABC Television Network and its Director Emeritus is Roy Disney (brother of the late Walt Disney) who was inducted into the Knights of St. Gregory during the same ceremony with Fox Network owner Rupert Murdoch. ABC and Fox are both controlled by Rome through brother Knights of the Order of St. Gregory!
World War I: Petrochemicals
While prior to World War I America relied heavily on foreign supplies of chemicals, the increasing likelihood of U.S. intervention meant that the country would soon need its own domestic producer of chemicals. Looking back on the significance of the war for Monsanto, Queeny's son Edgar remarked, "There was no choice other than to improvise, to invent and to find new ways of doing all the old things. The old dependence on Europe [Hitler's IG Farben in Nazi Germany] was, almost overnight, a thing of the past." Among other problems, Monsanto researchers discovered that pages describing German chemical processes had been ripped out of library books. Monsanto developed several pharmaceutical products, including phenol as an antiseptic, in addition to acetylsalicyclic acid, or aspirin.
Under Edgar Queeny's direction Monsanto, now the Monsanto Chemical Company, began to substantially expand and enter into an era of prolonged growth. Acquisitions expanded Monsanto's product line to include the new field of petrochemical plastics and the manufacture of phosphorus.
1976, Monsanto announced plans to phase out production of polychlorinated biphenyl (PCB).
In 1979 a lawsuit was filed against Monsanto and other manufacturers of agent orange, a defoliant used during the Vietnam War. Agent orange contained a highly-toxic chemical known as dioxin, and the suit claimed that hundreds of veterans had suffered permanent damage because of the chemical. In 1984 Monsanto and seven other manufacturers agreed to a $180 million settlement just before the trial began. With the announcement of a settlement Monsanto's share price, depressed because of the uncertainty over the outcome of the trial, rose substantially.
Also in 1984, Monsanto lost a $10 million antitrust suit to Spray-Rite, a former distributor of Monsanto agricultural herbicides. The U.S. Supreme Court upheld the suit and award, finding that Monsanto had acted to fix retail prices with other herbicide manufacturers.
In August 1985, Monsanto purchased G. D. Searle, the "NutraSweet" firm. NutraSweet, an artificial sweetener, had generated $700 million in sales that year, and Searle could offer Monsanto an experienced marketing and a sales staff as well as real profit potential - not to mention the fact that Searle's CEO Secretary of Defense Donald Rumsfeld was well-connected among a cabal of corrupt politicians in Washington DC. Since the late 1970s the company had sold nearly 60 low-margin businesses and, with two important agriculture product patents expiring in 1988, a major new cash source was more than welcome. What Monsanto didn't count on, however, was the controversy surrounding Searle's intrauterine birth control device called the Copper-7.
Soon after the acquisition, disclosures about hundreds of lawsuits over Searle's IUD surfaced and turned Monsanto's takeover into a public relations disaster. The disclosures, which inevitably led to comparisons with those about A. H. Robins, the Dalkan Shield manufacturer that eventually declared Chapter 11 bankruptcy, raised questions as to how carefully Monsanto management had considered the acquisition. In early 1986 Searle discontinued IUD sales in the United States. By 1988 Monsanto's new subsidiary faced an estimated 500 lawsuits against the Copper-7 IUD. As the parent company, Monsanto was well insulated from its subsidiary's liabilities by the legal "corporate veil".
Toward the end of the 1980s, Monsanto faced continued challenges from a variety of sources, including government and public concern over hazardous wastes, fuel and feedstock costs, and import competition. At the end of the 99th Congress, then President Ronald Reagan signed a $8.5 billion, five-year cleanup superfund reauthorization act. Built into the financing was a surcharge on the chemical industry created through the tax reform bill. Biotechnology regulations were just being formulated, and Monsanto, which already had types of genetically engineered bacteria ready for testing, was poised to be an active participant in the GMO biotech field.
In keeping with its strategy to become a leader in the health field, Monsanto and the Washington University Medical School entered into a five-year research contract in 1984. Two-thirds of the research was to be directed into areas with obviously commercial applications, while one-third of the research was to be devoted to theoretical work. One particularly promising discovery involved the application of the bovine growth factor, MARKETED as a way to greatly increase milk production.
In the burgeoning low-calorie sweetener market, challengers to NutraSweet were putting pressure on Monsanto. Pfizer Inc., a pharmaceutical company, was preparing to market its product, called alitame, which it claimed was far sweeter than NutraSweet and better suited for baking.
In an interview with Business Week, senior vice-president for research and development Howard Schneiderman commented, "To maintain our markets - and not become another steel industry - we must spend on research and development." Monsanto, which has committed 8% of its operating budget to research and development, far above the industry average, hoped to emerge in the 1990s as one of the leaders in the fields of biotechnology and pharmaceuticals that are only now emerging from their nascent stage.
By the end of the 1980s, Monsanto had restructured itself and become a producer of specialty chemicals, with a focus on biotechnology products. Monsanto enjoyed consecutive record years in 1988 and 1989 - sales were $8.3 billion and $8.7 billion, respectively. In 1988 the Food and Drug Administration (FDA) approved Cytotec, a drug that prevents gastric ulcers in high-risk cases. Sales of Cytotec in the United States reached $39 million in 1989.
The Monsanto Chemical Co. unit prospered with products like Saflex, a type of nylon carpet fiber. The NutraSweet Company held its own in 1989, contributing $180 million in earnings, with growth in the carbonated beverage segment (which Monsanto originated from since 1901 seed money from Coca-Cola to produce carcinogenic Saccharin). Almost 500 new products containing NutraSweet were introduced in 1989, for a total of 3,000 products.
Monsanto continued to invest heavily in research and development, with 7% of sales allotted for R&D. The investment began to pay off when the research and development department developed an all-natural fat substitute called Simplesse. The FDA declared in early 1990 that the Simplesse product was "generally recognized as safe" (GRAS) for use in frozen desserts. That year, the NutraSweet Company introduced Simple Pleasures frozen dairy dessert. Monsanto hoped to see Simplesse used eventually in salad dressings, yogurt, and mayonnaise.
Despite these successes, Monsanto remained frustrated by delays in obtaining FDA approval for bovine somatotropin (BST), a hormore chemical MARKETED to increase milk production in cows that causes mastitis (pus milk). Opponents to BST said it would upset the balance of supply and demand for milk, but Monsanto countered that BST would provide high-quality food supplies to consumers worldwide.
The final year of the 1980s also marked Monsanto's listing for the first time on the Tokyo Stock Exchange. Monsanto officials expected the listing to improve opportunities for licensing and joint venture agreements.
Link: http://bestmeal.info/monsanto/company-history.shtml#timeline
... to be continued
